To study the predictive value of illness perceptions, fear of cancer recurrence, medication beliefs and quality of life on adherence to endocrine treatment at 12 months. To study adherence to endocrine therapy at 3 and 6 months. To compare cross-…
ID
Bron
Verkorte titel
Aandoening
This study will include women with stage I-III breast cancer who are scheduled to receive adjuvant ET without adjuvant chemotherapy
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
To study the predictive value of illness perceptions, fear of cancer recurrence, medication beliefs and quality of life on adherence to endocrine treatment at 12 months
Achtergrond van het onderzoek
Rationale: Illness perceptions (IPs), medication beliefs, Fear of cancer recurrence (FCR) and quality of life (QoL) may influence adherence to endocrine therapy (ET) in patients with breast cancer.
Objective: To analyze the predictive value of IPs, medication beliefs and QoL on adherence to adjuvant ET and to create a prediction model with adherence as outcome.
Study design: Descriptive study.
Study population: Women with stage I-III breast cancer treated for their disease at the Leiden University Medical Center, the Haaglanden Medical Center and the Saitama Cancer Center in Japan.
Main study parameters/endpoints: Adherence to ET in the first year in patients with early breast cancer and its association with illness perceptions, medication beliefs and QoL.
Doel van het onderzoek
To study the predictive value of illness perceptions, fear of cancer recurrence, medication beliefs and quality of life on adherence to endocrine treatment at 12 months.
To study adherence to endocrine therapy at 3 and 6 months.
To compare cross-cultural differences of illness perceptions, medication beliefs, quality of life and adherence to ET in women with breast cancer.
To determine the ability to retain/resume work.
To observe and evaluate occurrence of side effects (grade III/IV).
Onderzoeksopzet
Patients will be asked to fill out multiple questionnaires at the following time points; at baseline and after 3, 6 and 12 months of starting with endocrine therapy.
Onderzoeksproduct en/of interventie
none
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
This study will include women with stage I-III breast cancer who are scheduled to receive adjuvant ET without adjuvant chemotherapy. Patients will be recruited from the Leiden University Medical Center in the Netherlands, the Haaglanden Medical Center in the Netherlands and the Saitama Cancer Center in Japan.
To be eligible to participate in this study, a subject must meet all of the following criteria:
• Female patients aged 18 years or older;
• Stage I, II or III HR-positive breast cancer;
• Scheduled adjuvant endocrine therapy.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
• Patients with M+ tumors;
• Patients receiving neoadjuvant endocrine therapy;
• Patients receiving (neo)adjuvant chemotherapy;
• Patients with other types of active cancer within the past 3 years;
• Previous use of endocrine therapy or chemotherapy;
• Medical or psychological condition which, in the opinion of the investigator, would not permit the patient to complete the study or sign meaningful informed consent.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8541 |
| Ander register | METC-LDD : N19.122 |